Log In
BCIQ
Print this Print this
 

TGOFO2N

  Manage Alerts
Collapse Summary General Information
Company Fabre-Kramer Pharmaceuticals Inc.
DescriptionBinds to dopamine D2 receptor, dopamine D3 receptor, serotonin (5-HT2C) receptor, serotonin (5-HT2A) receptor and histamine H1 receptor
Molecular Target Dopamine D2 receptor ; Serotonin (5-HT2) receptor
Mechanism of ActionSerotonin (5-HT2A) receptor antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today